MRVI
Maravai LifeSciences Holdings, Inc.
$4.40
Stable Earnings Power
40%
P/Adj-EPS × Normalized Multiple
Strong
·
Conviction
Undervalued
Trading 79.9% below fair value
You pay
$4.40
Bear
$18.79
Fair
$21.92
Bull
$25.05
Bear
$18.79
+327.0%
$1.86 × 12x P/E
Fair
$21.92
+398.2%
$1.86 × 14x P/E
Bull
$25.05
+469.3%
$1.86 × 16x P/E
Key Value Driver
Normalized P/E multiple (14x base case)
Implied Market Multiple
2.4x
Summary
Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $5.25 from 14 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $21.92 per share.
Warnings
Wall Street's average price target is $5.25 (from 14 analysts). Our estimate is 397% above the consensus -- consider that gap carefully.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples